RE:RE:The big one...lscfa wrote: I suspect the legal fees incurred are really for Nasdaq lisitng nonsense and nothing to do with DD on market opportunities.
Listing on NASDAQ could put a price tag on CZO's pipeline as the pipeline also reached key valuation milestones from PGX scale-up and licensing, to the first human clinical data for the avenanthramide pill, and a clincal trial decision for PGX-YBG/fibrosis. The wound healing study with the Angiogenesis Foundation also opens the door to a potential partnership.
CZO wouldn't be announcing this if it wasn't confident in the results. Head-to-head data for PGX-YBG in the $1 billion yeast beta glucan immune booster market as PGX scales up. PGX-YBG has shown itself 5X more immune stimulatory in certain studies. Does CZO have the emerging gold standard? From the news release: "
additional research at McMaster University clearly showed that PGX-YBG gets into the macrophage cell. This important finding further supports the potential of YBG to act as a stand-alone and/or a carrier for other bioactives when transported by macrophages cells." Does CZO have a trojan horse with PGX-YBG that can deliver a payload to macrophages for distribution of drugs throughout the body? - "Protocol designed for a head-to-head study in animals for testing immune properties of PGX-YBG against a commercial formulation."